Register to see more features including:
No result found
Focused on supporting entrepreneurs who are building potential high-growth companies in cleantech, software, biosciences and digital health.
Base Ventrues, founded by Erik Moore, is a seed-stage fund investing in technology companies. Current portfolio includes Angellist, Virool, Surfair, SocialCal, Tracks.by/Hipset, Priceonomics, MightyText, and others. Successful exits include Socialcam (acquired by Autodesk), and Appstores (acquired by InMobi).
Erik Moore is the founder and Managing Director of Base Ventures. Erik is a passionate angel investor, entrepreneur, creative thinker, and an unabashed optimist.
After a rewarding fifteen-year career in investment banking, Erik secured an early retirement from Merrill Lynch in 2011 and at that point began pursuing his passion for entrepreneurship.
Erik formed Base Ventures from a love for investing in trailblazing tech start-ups. During the past 12-years, Erik has invested in almost two dozen trailblazing start-ups.
Erik was a seed investor in Zappos.com which was sold to Amazon for $1.2b and Agencourt Biosciences which was sold to Beckman Coulter for $270mm.
Writer contributor to Segment News, USA Herald, Boston.com, Indy, Dictated and more about how individuals can succeed at selling and developing a positive company culture. Writer reviewer of independent films and documentaries that inspire the human spirit. Promoter of talent local and international via the lively arts foundation our next 2 performances are "Mystic India" a Bollywood production October 18th and then our community favorite "Nutcracker" where we work with the school district on bussing in migrant children to watch the ballet under Arts in the Schools program.
PolySkope simultaneously detects all the most common food borne pathogens that cause death and financial ruin. Using our team's skill and expertise in clinical diagnostic multiplex assay development, we have created a multiplex pathogen detection RT-PCR assay for food. Simple and easy to use, our test uses a single overnight enrichment and sample prep to detect Shiga Toxin E. coli (including O157:H7), Salmonella and Listeria. This will reduce the cost of materials, labor, reagents, disposables, space, incubatory space, equipment and expensive instruments 3-fold. It makes comprehensive testing easy and affordable. Our C.S.O. and lead inventor, Michael Centola, previously founded Crescendo Bioscience and was lead inventor of their Vectra DA assay which sold for $270 M. This financing will take our technology through AOAC and ISO validation and into first sales.
The LinkSēq™ HLA product line is redefining the way histocompatibility laboratories type patients and donors for solid organ and stem cell transplantation. LinkSēq™ is the world's fastest, simplest method of tissue typing, providing more relevant genetic data, and dramatically increasing laboratory efficiency and cost structure. The company's core technology has been applied to companion diagnostics (adverse drug effects) and other genetic diseases (e.g. celiac disease), with an expanding catalog of products.
Currently, there is no single test to detect and predict multiple types of cancer throughout the body. Instead, multiple different tests are used to find cancer in a variety of ways. The diagnostic test Lazarus is developing will make checking for cancer as simple as checking cholesterol levels and may become a common part of a regular physical, leading to earlier detection, lower treatment costs and better patient outcomes.
MedTech Reveal - Color Changing Alcohol Detection Patch
MedTeh SplitCup (Formerly AdheRx) - Color Changing Compliance Specimen Cup
Chemical detection by way of molecular imprint in the form of a Split Specimen Cup, Swab and Patch, to detect the presence of various molecules to ensure clinical trial compliance, adherence to prescription medication, resistance to substance abuse, and to verify surface cleanliness in hospitals and food service areas. These detections are molecular, instantaneous, and can be detected at the micromolar level.
Current ventures include Alexian Brother Behavioral Health Hospital, North Shore University Health Center, and Rush University Medical Center.
Xcell Biosciences is a San Francisco-based life sciences company that has developed an innovative research and diagnostics platform utilizing its technology for capturing and growing tumor cells and immune cells directly from patient blood. By rapidly growing and expanding this rare cancer cell population into miniature tumors, the company has overcome key sample size limitations significantly impacting the ability to perform genetic analysis on this population of cells. As a result, the company is able to capture the comprehensive set of genetic information for each patient’s cancer and track changes to that dataset overtime, enabling the company to create a highly scalable, first-in-class big data solution for cancer. This patient-centric company is developing the platform as a high content liquid biopsy tool for cancer research and clinical use, including screening, monitoring, and managing unpredicted changes to a patient’s disease
Roka pathogen detection assays combine the full power of Target Capture, Transcription-Mediated Amplification, and Hybridization Protection Assay to provide the most advanced food safety testing solutions available
At Twist Bioscience, our expertise is synthetic DNA. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. The Twist Bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. For more information, please visit www.twistbioscience.com .
A division of the Maricopa Corporate College, the Center for Entrepreneurial Innovation (CEI) is a Phoenix business incubator dedicated to supporting technology-related startup and early-stage companies in the mission of quality JOB CREATION. CEI provides VALIDATION and COMMERCIALIZATION assistance for companies in the industries of: Medical Devices; Biosciences/Biotechnologies; Clean and Renewable Energies; Emerging Technologies and Software Development. In addition, CEI provides onsite rapid prototyping / 3D printing through PADT StartUpLabs, competitive intelligence services, business development and commercialization guidance with a seasoned Entrepreneur-in-Residence, office and wet lab space, and additional access to specialty biotechnology equipment. CEI does not take any equity in its client companies but does facilitate entrepreneur-investor relations and coaches its clients through investment principles, valuation, pitch, and more. Website: http://www.ceigateway.com
Investing in world-class bioscience research and training on behalf of the UK public. Funded by government, we fund research and postgraduate training at universities and research institutes in the UK through research grants.
Advanced crop technology for biofuel production ,Advanced crop technology focusing on energy feedstock. High quality biofuel production.
Tempo Bioscience (Tempo) is a technology development company. Our proprietary technologies and products serve as tools for pre-clinical drug discovery, cellular toxicology screening, drug development, and non-animal-based testing for the biotechnology, pharmaceutical, and chemical industries. Our main focus is on developing and manufacturing biosensors which can be incorporated into a variety of human cell types for pre-clinical discovery and drug development. Our biosensors are designed to work with immortalized human cell lines, human primary cells, and human stem cell (iPSC-) derived cell types. We strongly believe that advanced human cellular biosensor technologies from Tempo complement animal model studies, thereby strengthening scientific discoveries and drug development. For more info on our products, visit .
Aquasium Limited was formed by John Cumberland and John Salter in 1995 with the specific aim of acquiring and building up companies in the broader technology sector which had good mature technology and products but were not realising their full potential.
Companies in all technology sectors, except biosciences, were considered. The idea was to target businesses that already had a mature, proven technology, which had not been fully developed or exploited. Wherever possible, the acquired companies would be encouraged to market their products throughout the world, not only to increase sales, but also to avoid the impact of localised economic recessions.
BioAxone is committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorders. Led by a passionate management team augmented by 20 years of pioneering research, the company has identified and is developing a pipeline of drugs focused on nerve repair and regeneration.
The company’s lead program licensed to Vertex Pharmaceuticals is actively recruiting in a Phase 2b/3 clinical trial to treat acute spinal cord injury. The SPRING SCI clinical trial is explained here.
The Christopher Reeve Foundation published a blog about “A Drug and its champion. Persistence matters” .
For summary of the BioAxone programs click here
Welcome to TFC BioSciences, Inc. TFC BioSciences develops and manufactures liposome-based fluorescence detection systems – Fluorosomes® – for applications in drug discovery and related fields. Utilizing the Fluorosome® platform we are continuously expanding our technology to develop smart tools for “ADMET” studies in drug discovery.
The basic platform – Fluorosome®–trans – measures passive drug diffusion through the membrane bilayer, yielding the property “membrane permeability”, which is predictive of tissue absorption e.g. oral absorption of a drug.
Our flagship product is the Fluorosome®–trans-pgp assay. This high throughput inhibition assay is an innovative “stand alone” platform for characterizing P-glycoprotein/drug interactions. The P-glycoprotein is a key drug efflux pump responsible for poor oral drug absorption and penetration into the brain, as well as multi-drug resistance in tumors. Unlike older vesicle assay systems formed from heterogeneous membrane fragments, Fluorosome-trans-pgp consists of highly purified functional P-glycoprotein reconstituted in unilamellar liposomes.
ENANTA ANNOUNCES U.S. FDA HAS APPROVED ABBVIE’S SUPPLEMENTAL NEW DRUG APPLICATION FOR USE OF VIEKIRA PAK® WITHOUT RIBAVIRIN IN GENOTYPE 1B CHRONIC HEPATITIS C PATIENTS WITH COMPENSATED CIRRHOSIS -- more
Mitralign: Tewksbury firm’s device used in landmark heart surgery -- more
Enanta Pharmaceuticals Announces Investigational Regimen Containing Enanta’s Next-Generation Protease Inhibitor ABT-493 Demonstrates High Sustained Virologic Response Rates in Phase 2 Studies in Patients with Chronic Hepatitis C -- more
Enanta Announces Approval of Tablets) In Japan for the Treatment of Genotype 1 Chronic Hepatitis C -- more
Xencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb� Cytotoxic Fc Domain -- more
Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation -- more
Agilent (A) Acquires Seahorse Bioscience and its XF Technology for $235 Million -- more
A Tribute to Ned Olivier by Jonathan Fleming and Matt Gibbs -- more
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines -- more
Extend Biosciences Inc. is an emerging biotechnology company developing a novel drug delivery platform technology that improves the pharmacokinetic properties of peptides and proteins.
Peptides have been particularly challenging to bring to market because they are removed from circulation prior to administering therapeutic value.
Our proprietary platform technology significantly improves the circulating half-life and bioavailability of peptides and proteins, enabling the scientific community to truly develop potent and specific drugs.
Our mission is to revolutionize drug delivery and give patients a better quality of life.
Amarillo Biosciences is a specialty biopharmaceutical company developing a patented formulation of interferon-alpha that's given orally in low doses, making it safer and less expensive than current injectable formulations.
Amarillo Biosciences is working with global partners to conduct clinical studies to establish the safety and efficacy of low-dose interferon-alpha given in the form of orally dissolving lozenges to treat a number of significant human diseases, including influenza and hepatitis C
The choices we make today, big and small, will impact our world tomorrow.
From bread to biofuels, we partner with customers to deliver high-performance products and solutions that are better, safer, and cleaner.
Find out how we can partner for a better tomorrow, today.
Generator of energy on site for use on demand. Produces gas for cooking, heating and/or electricity and thermal power for heating and hot water for kitchen and bathroom.
Modular product from a normal house to a factory, shopping center, town, etc.
Groken Bioscience provides you with a health monitoring tool to explore your "Other Genome", the genome of trillions of microorganism that share your body space. This "newly discovered organ" is found to have potentially overwhelming impact on human health, from obesity, heart health, respiratotary problems to behaviours.
Unlike our genome, you are able to change your microbiome. With this amazing potential, it is important to understand your microbiome. Using cutting edge genome sequencing and bioinformatics analysis, you can know what is your microbiome, how is it related to others and its changes overtime, we provide you actionable suggestions to change your microbiome hense improving your health.
We are the first in Asia and China, using big data on microbiome, to provide a tool for individuals to discover their microbiome. We aim at building an Asian specific microbiome database and an interactive interface to let individuals monitor and control this important health factor.
Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Our tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.
Sonify is developing a medical device based on low-intensity ultrasound as an early-stage adjuvant treatment for melanoma and other skin cancers. With data in hand from our proof-of-concept experiments, we're looking to complete our currently open partially filled funding round. Next steps include beginning animal trials.
Armune has completed development and validated Apifiny™, a new prostate cancer diagnostic assay. The company has a clear path to revenue by offering Apifiny as a Laboratory Developed Test (LDT) in accordance with the Clinical Laboratory Improvement Amendments (CLIA) guidelines. CLIA compliance is monitored by the Centers for Medicare & Medicaid Services (CMS) and applies to all laboratory testing (except research) performed on humans in the U.S. Plans are in place to develop a prognostic that can differentiate between indolent and aggressive prostate cancer.
The technology can potentially be used as a diagnostic and prognostic for lung cancer and breast cancer.
Thank you for creating the collection.
You can add startups from the list below